We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$511M 8.73%
7,957,128
+7,654,485
+2,529% +$541M
INCY icon
2
Incyte
INCY
$23.4B
$314M 5.36%
3,697,650
+3,649,150
+7,524% +$293M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$299M 5.11%
3,546,444
+3,526,244
+17,457% +$290M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$260M 4.45%
1,420,489
+1,303,500
+1,114% +$228M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$242M 4.13%
1,321,404
+1,305,104
+8,007% +$223M
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$189M 3.22%
4,057,411
+3,561,864
+719% +$167M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$176M 3%
1,341,428
+1,170,278
+684% +$151M
CELG
8
DELISTED
Celgene Corp
CELG
$171M 2.92%
1,850,000
+1,832,212
+10,300% +$174M
RDUS
9
DELISTED
Radius Health, Inc.
RDUS
$167M 2.85%
6,840,785
+6,781,685
+11,475% +$148M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.36B
$156M 2.66%
+3,128,134
New +$167M
HALO icon
11
Halozyme
HALO
$9.23B
$142M 2.42%
+8,247,860
New +$133M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$35.7B
$140M 2.39%
1,927,394
+1,660,089
+621% +$127M
ARGX icon
13
argenx
ARGX
$53.8B
$134M 2.28%
944,639
+924,739
+4,647% +$117M
ELV icon
14
Elevance Health
ELV
$80.9B
$102M 1.74%
360,739
+105,722
+41% +$28.9M
TDOC icon
15
Teladoc Health
TDOC
$1.7B
$95.3M 1.63%
1,435,012
+60,718
+4% +$3.54M
NKTR icon
16
Nektar Therapeutics
NKTR
$2.31B
$93.7M 1.6%
175,512
+146,844
+512% +$73.6M
ISRG icon
17
Intuitive Surgical
ISRG
$122B
$88.4M 1.51%
505,446
+52,449
+12% +$8.99M
ILMN icon
18
Illumina
ILMN
$28.2B
$84M 1.43%
234,580
-30,331
-11% -$9.58M
ALGN icon
19
Align Technology
ALGN
$12.7B
$83.9M 1.43%
306,595
-28,084
-8% -$8.48M
EXEL icon
20
Exelixis
EXEL
$14.1B
$82.9M 1.42%
3,878,800
+3,738,300
+2,661% +$78.3M
ABT icon
21
Abbott
ABT
$175B
$80.5M 1.38%
957,595
-82,992
-8% -$6.53M
MDT icon
22
Medtronic
MDT
$106B
$75.9M 1.3%
779,411
+288,505
+59% +$26.3M
MGNX icon
23
MacroGenics
MGNX
$285M
$74.6M 1.27%
4,395,264
+3,604,959
+456% +$61.9M
VYGR icon
24
Voyager Therapeutics
VYGR
$192M
$73M 1.25%
+2,680,283
New +$61.3M
AKCA
25
DELISTED
Akcea Therapeutics Inc
AKCA
$72.7M 1.24%
3,100,768
+2,596,357
+515% +$64.1M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.